NO308447B1 - Stabilisert farmasøytisk preparat og fremgangsmÕte for fremstilling av dette - Google Patents

Stabilisert farmasøytisk preparat og fremgangsmÕte for fremstilling av dette

Info

Publication number: NO308447B1
Authority: NO; Norway
Prior art keywords: preparation; carboxylate anion; solvent; anion content; stabilized pharmaceutical
Prior art date: 1993-09-29

Application number

NO943583A

Other languages

English (en)

Norwegian (no)

Other versions

NO943583D0 (no

NO943583L (no

Inventor

Shreerham Narahari Agharkar

Uday S Gogate

Thomas Cavanak

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-09-29

Filing date

1994-09-27

Publication date

2000-09-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22433231&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO308447(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-09-27 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

1994-09-27 Publication of NO943583D0 publication Critical patent/NO943583D0/no

1995-03-30 Publication of NO943583L publication Critical patent/NO943583L/no

2000-09-18 Publication of NO308447B1 publication Critical patent/NO308447B1/no

Links

238000000034 method Methods 0.000 title 1
239000000825 pharmaceutical preparation Substances 0.000 title 1
239000002904 solvent Substances 0.000 abstract 4
-1 carboxylate anion Chemical class 0.000 abstract 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
239000004359 castor oil Substances 0.000 abstract 2
235000019438 castor oil Nutrition 0.000 abstract 2
230000015556 catabolic process Effects 0.000 abstract 2
238000006731 degradation reaction Methods 0.000 abstract 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 abstract 2
KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 abstract 1
229930012538 Paclitaxel Natural products 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 abstract 1
229940034982 antineoplastic agent Drugs 0.000 abstract 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
239000006227 byproduct Substances 0.000 abstract 1
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 abstract 1
229940127093 camptothecin Drugs 0.000 abstract 1
VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
229960001592 paclitaxel Drugs 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 abstract 1
229960001278 teniposide Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Steroid Compounds (AREA)

NO943583A 1993-09-29 1994-09-27 Stabilisert farmasøytisk preparat og fremgangsmÕte for fremstilling av dette NO308447B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US12802693A	1993-09-29	1993-09-29

Publications (3)

Publication Number	Publication Date
NO943583D0 NO943583D0 (no)	1994-09-27
NO943583L NO943583L (no)	1995-03-30
NO308447B1 true NO308447B1 (no)	2000-09-18

Family

ID=22433231

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO943583A NO308447B1 (no)	1993-09-29	1994-09-27	Stabilisert farmasøytisk preparat og fremgangsmÕte for fremstilling av dette

Country Status (28)

Country	Link
US (1)	US5504102A (de)
EP (1)	EP0645145B1 (de)
JP (1)	JP3447386B2 (de)
KR (1)	KR100515631B1 (de)
CN (1)	CN1140297C (de)
AT (1)	ATE149843T1 (de)
AU (1)	AU686651B2 (de)
BE (1)	BE1007987A5 (de)
BR (1)	BR1100361A (de)
CA (1)	CA2132936C (de)
CY (1)	CY2035A (de)
CZ (2)	CZ287358B6 (de)
DE (1)	DE69402022T2 (de)
DK (1)	DK0645145T3 (de)
ES (2)	ES2098842T3 (de)
FI (1)	FI115825B (de)
GR (1)	GR3023583T3 (de)
HK (1)	HK96797A (de)
HU (1)	HU217962B (de)
IL (1)	IL111065A (de)
IT (1)	IT1279383B1 (de)
NO (1)	NO308447B1 (de)
NZ (1)	NZ264526A (de)
PL (1)	PL176826B1 (de)
RU (1)	RU2107500C1 (de)
SG (1)	SG50479A1 (de)
TW (1)	TW406020B (de)
ZA (1)	ZA947482B (de)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2224200T3 (es) *	1992-11-27	2005-03-01	Mayne Pharma (Usa) Inc.	Composicion inyectable estable de paclitaxel.
US20030133955A1 (en) *	1993-02-22	2003-07-17	American Bioscience, Inc.	Methods and compositions useful for administration of chemotherapeutic agents
US20030068362A1 (en) *	1993-02-22	2003-04-10	American Bioscience, Inc.	Methods and formulations for the delivery of pharmacologically active agents
US6096331A (en)	1993-02-22	2000-08-01	Vivorx Pharmaceuticals, Inc.	Methods and compositions useful for administration of chemotherapeutic agents
US6749868B1 (en)	1993-02-22	2004-06-15	American Bioscience, Inc.	Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en)	1993-02-22	2003-03-25	American Bioscience, Inc.	Compositions and methods for administration of pharmacologically active compounds
US6753006B1 (en) *	1993-02-22	2004-06-22	American Bioscience, Inc.	Paclitaxel-containing formulations
US5610173A (en) *	1994-01-07	1997-03-11	Sugen, Inc.	Formulations for lipophilic compounds
US6335356B1 (en)	1994-01-07	2002-01-01	Sugen, Inc.	Method of treating a patient by parenteral administration of a lipophilic compound
US5631287A (en) *	1994-12-22	1997-05-20	Alcon Laboratories, Inc.	Storage-stable prostaglandin compositions
US6011062A (en) *	1994-12-22	2000-01-04	Alcon Laboratories, Inc.	Storage-stable prostaglandin compositions
NL9500340A (nl) *	1995-02-22	1996-10-01	Yew Tree Pharmaceuticals B V	Gestabiliseerde paclitaxel-oplossing en farmaceutisch preparaat dat deze oplossing bevat.
US5726181A (en) *	1995-06-05	1998-03-10	Bionumerik Pharmaceuticals, Inc.	Formulations and compositions of poorly water soluble camptothecin derivatives
US6774278B1 (en)	1995-06-07	2004-08-10	Cook Incorporated	Coated implantable medical device
DE19536165A1 (de) *	1995-09-28	1997-04-03	Basf Ag	Verfahren zur Reinigung von alkoxylierten Fetten
US6245805B1 (en) *	1995-10-26	2001-06-12	Baker Norton Pharmaceuticals, Inc.	Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6964946B1 (en)	1995-10-26	2005-11-15	Baker Norton Pharmaceuticals, Inc.	Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
WO1997023208A1 (en) *	1995-12-21	1997-07-03	Genelabs Technologies, Inc.	Taxane composition and method
US6576636B2 (en) *	1996-05-22	2003-06-10	Protarga, Inc.	Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en)	1996-05-22	1998-08-18	Neuromedica, Inc.	DHA-pharmaceutical agent conjugates of taxanes
KR100358934B1 (ko) *	1996-09-13	2003-01-29	주식회사한국신약	탁솔을함유한주사용약제조성물
BR9713661A (pt) *	1996-12-30	2000-10-24	Battelle Memorial Institute	Formulação e método para o tratamento de neoplasmas por inalação
US6458373B1 (en) *	1997-01-07	2002-10-01	Sonus Pharmaceuticals, Inc.	Emulsion vehicle for poorly soluble drugs
US6316479B1 (en)	1997-05-19	2001-11-13	Sugen, Inc.	Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
BE1011216A3 (fr) *	1997-06-13	1999-06-01	Thissen En Abrege L T B Lab	Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition.
US5925776A (en) *	1997-12-24	1999-07-20	Schein Pharmacetical, Inc.	Polyethoxylated castor oil, process of making the same and formulations thereof
US7030155B2 (en) *	1998-06-05	2006-04-18	Sonus Pharmaceuticals, Inc.	Emulsion vehicle for poorly soluble drugs
US5922754A (en) *	1998-10-02	1999-07-13	Abbott Laboratories	Pharmaceutical compositions containing paclitaxel
AU1214400A (en) *	1998-10-20	2000-05-08	Ben Venue Laboratories, Inc.	Process for purification of solvents useful in the preparation of pharmaceuticalcompositions
US6017948A (en) *	1998-10-30	2000-01-25	Supergen, Inc.	Water-miscible pharmaceutical compositions
US6071952A (en) *	1998-12-02	2000-06-06	Mylan Pharmaceuticals, Inc.	Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
US6040330A (en) *	1999-01-08	2000-03-21	Bionumerik Pharmaceuticals, Inc.	Pharmaceutical formulations of taxanes
US7235583B1 (en)	1999-03-09	2007-06-26	Luitpold Pharmaceuticals, Inc.,	Fatty acid-anticancer conjugates and uses thereof
US6828346B2 (en) *	1999-10-25	2004-12-07	Supergen, Inc.	Methods for administration of paclitaxel
US6136846A (en)	1999-10-25	2000-10-24	Supergen, Inc.	Formulation for paclitaxel
CA2404370A1 (en) *	2000-03-24	2001-10-04	Baker Norton Pharmaceuticals, Inc.	Taxane-based compositions and methods of use
AU2001253336A1 (en)	2000-04-10	2001-10-23	Teva Pharmaceutical Industries Ltd.	Method 0f administration of paclitaxel-plasma protein formulation
ES2390066T3 (es)	2000-05-12	2012-11-06	Samyang Biopharmaceuticals Corporation	Procedimiento para la preparación de micelas poliméricas mediante separación de fase de un copolímero en bloque
US7217770B2 (en)	2000-05-17	2007-05-15	Samyang Corporation	Stable polymeric micelle-type drug composition and method for the preparation thereof
AU2001279168A1 (en) *	2000-08-02	2002-02-13	Atossa Healthcare, Inc.	Bimodal emulsions of taxanes and butyrate polyalcohol esters
CN1116875C (zh) *	2000-10-19	2003-08-06	南京振中生物工程有限公司	紫杉醇脂质组合物及其制备方法
US6410059B1 (en) *	2000-10-20	2002-06-25	Council Of Scientific And Industrial Research	Pharmaceutical composition containing cow urine distillate and an antibiotic
PL203300B1 (pl)	2000-10-31	2009-09-30	Akad Medyczna	Stabilna postać farmaceutyczna leku przeciwnowotworowego oraz sposób wytwarzania stabilnej postaci farmaceutycznej leku przeciwnowotworowego
DE60136490D1 (de)	2000-11-09	2008-12-18	Neopharm Inc	Sn-38-lipidkomplexe und verfahren zu ihrer verwendung
EP1337273A2 (de) *	2000-11-28	2003-08-27	Transform Pharmaceuticals, Inc.	Pharmazeutische zusammensetzungen enthaltend paclitaxel, dessen derivate und dessen pharmazeutisch denkbare saltze
US7169819B2 (en)	2000-12-05	2007-01-30	Childrens Hospital Los Angeles	Pharmaceutical compositions of fenretinide having increased bioavailability and methods of using the same
US7115565B2 (en)	2001-01-18	2006-10-03	Pharmacia & Upjohn Company	Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
PL207720B1 (pl) *	2001-01-25	2011-01-31	Bristol Myers Squibb Co	Sposób przygotowania preparatu farmaceutycznego i jego zastosowanie, farmaceutyczny produkt oraz sposób wytwarzania kompozycji farmaceutycznej
US8552054B2 (en)	2001-03-23	2013-10-08	Luitpold Pharmaceuticals, Inc.	Fatty amine drug conjugates
JP4634694B2 (ja) *	2001-03-23	2011-02-16	ルイトポルド・ファーマシューティカルズ・インコーポレーテッド	脂肪アルコール薬物複合体
DE10115740A1 (de) *	2001-03-26	2002-10-02	Ulrich Speck	Zubereitung für die Restenoseprophylaxe
AU2002303210A1 (en)	2001-04-06	2002-10-21	Cytorex Biosciences, Inc.	Pharmacologically active strong acid solutions
WO2003030864A1 (en) *	2001-05-29	2003-04-17	Neopharm, Inc.	Liposomal formulation of irinotecan
KR100774366B1 (ko)	2001-09-10	2007-11-08	주식회사 중외제약	파클리탁셀 주사제 조성물
KR20030023369A (ko) *	2001-09-13	2003-03-19	한국과학기술연구원	화학색전용 파클리탁셀 유성 조성물, 그의 제형 및 제조방법
US20030054042A1 (en) *	2001-09-14	2003-03-20	Elaine Liversidge	Stabilization of chemical compounds using nanoparticulate formulations
US6710195B2 (en) *	2001-11-26	2004-03-23	Supergen, Inc.	Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
AU2002357012A1 (en) *	2001-11-27	2003-06-10	Transform Pharmaceuticals, Inc.	Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
IL163666A0 (en)	2002-02-22	2005-12-18	New River Pharmaceuticals Inc	Active agent delivery systems and methods for protecting and administering active agents
AU2003230691A1 (en) *	2002-03-20	2003-10-08	Elan Pharma International Ltd.	Nanoparticulate compositions of angiogenesis inhibitors
US20080220075A1 (en) *	2002-03-20	2008-09-11	Elan Pharma International Ltd.	Nanoparticulate compositions of angiogenesis inhibitors
CZ294371B6 (cs) *	2002-06-10	2004-12-15	Pliva - Lachema, A. S.	Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
JP4454019B2 (ja) *	2002-07-15	2010-04-21	アルコン，インコーポレイテッド	眼薬送達のための生体侵食性フィルム
US20060030578A1 (en) *	2002-08-20	2006-02-09	Neopharm, Inc.	Pharmaceutically active lipid based formulation of irinotecan
WO2004035032A2 (en) *	2002-08-20	2004-04-29	Neopharm, Inc.	Pharmaceutical formulations of camptothecine derivatives
DE10244847A1 (de) *	2002-09-20	2004-04-01	Ulrich Prof. Dr. Speck	Medizinische Vorrichtung zur Arzneimittelabgabe
US20040122081A1 (en) *	2002-11-08	2004-06-24	Gogate Uday Shankar	Pharmaceutical compositions and methods of using taxane derivatives
US20050054716A1 (en) *	2002-11-08	2005-03-10	Gogate Uday Shankar	Pharmaceutical compositions and methods of using taxane derivatives
US20060263327A1 (en) *	2003-03-19	2006-11-23	Gerhard Eidenhammer	Method for the production of a stable injectable formulation made of difficult to dissolve antineoplastic active substances
RU2236852C1 (ru) *	2003-06-23	2004-09-27	Закрытое акционерное общество "ДЕСКО"	Средство для ингибирования репродукции оболоченных вирусов, способ его получения, фармацевтическая композиция и способ ингибирования вирусных инфекций
EP1648988A1 (de) *	2003-07-24	2006-04-26	Dabur Research Foundation	Verfahren zur reinigung von nichtionischen lösungsmitteln für stabilisierte pharmazeutische formulierungen zur injektion
US20050016926A1 (en) *	2003-07-24	2005-01-27	Dabur Research Foundation	Stabilized formulation
US7311901B2 (en)	2003-10-10	2007-12-25	Samyang Corporation	Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
EP1694660B1 (de)	2003-12-12	2009-04-08	Quiral Quimica Do Brasil	Verfahren zur herstellung von wasserfreien und hydratisierten pharmazeutischen wirkstoffen (apis); aus diesen hergestellte stabile pharmazeutische zusammensetzungen und anwendungen für diese zusammensetzungen
EP1694242B1 (de) *	2003-12-17	2014-04-16	Bionumerik Pharmaceuticals, Inc.	Verfahren zur herstellung von pharmazeutischen 7-(2-trimethylsilylethyl) camptothecin formulierungen
JP4433918B2 (ja) *	2004-07-15	2010-03-17	コニカミノルタエムジー株式会社	画像形成方法
KR100651728B1 (ko) *	2004-11-10	2006-12-06	한국전자통신연구원	정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
GT200500310A (es)	2004-11-19	2006-06-19		Compuestos organicos
US7361683B2 (en) *	2004-11-24	2008-04-22	Yung Shin Pharm. Ind., Co., Ltd	Paclitaxel aqueous injection solution and methods for preparing the same
SA06270147B1 (ar)	2005-06-09	2009-12-22	نوفارتيس ايه جي	عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
CN100548274C (zh) *	2006-01-12	2009-10-14	永信药品工业股份有限公司	紫杉醇水性注射液及其制备方法
US8242165B2 (en) *	2006-10-26	2012-08-14	Creighton University	Mucoadhesive nanoparticles for cancer treatment
KR20100100949A (ko)	2008-01-08	2010-09-15	브리스톨-마이어스 스큅 컴퍼니	증식성 질환의 치료를 위한 튜불린 조정제와 항-ｃｔｌａ４ 항체의 조합물
CN101939001B (zh) *	2008-02-20	2012-06-20	埃科特莱茵药品有限公司	用于治疗卵巢癌的含有紫杉醇的组合
DE102008059201A1 (de) *	2008-11-27	2010-06-02	GÖPFERICH, Achim, Prof. Dr.	In situ präzipitierende Arzneistofflösungen
EP2204167A1 (de)	2009-01-05	2010-07-07	Azad Pharma AG	Pharmazeutische Mikroemulsion zur Prävention von supramolekularer Aggregation von ampiphilen Molekülen
LT2769737T (lt)	2009-07-20	2017-06-26	Bristol-Myers Squibb Company	Anti-ctla4 antikūno derinys su etopozidu, skirtas sinerginiam proliferacinių ligų gydymui
AR093275A1 (es)	2010-03-17	2015-05-27	Centro De Excelencia En Productos Y Procesos De Cordoba (Ceprocor)	Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos
WO2012063182A1 (en) *	2010-11-08	2012-05-18	Cadila Pharmaceuticals Limited	Pharmaceutical composition of taxoids
WO2014028704A1 (en) *	2012-08-15	2014-02-20	Yung Shin Pharm. Ind. Co., Ltd.	Stable pharmaceutical formulation of cabazitaxel
WO2014123935A1 (en) *	2013-02-05	2014-08-14	1Globe Health Institute Llc	Biodegradable and clinically-compatible nanop articles as drug delivery carriers
EP2777691A1 (de) *	2013-03-14	2014-09-17	Pharmachemie B.V.	Taxoid - Reinigung der flüssigen Hilfsstoffen
WO2016005962A2 (en) *	2014-07-11	2016-01-14	Dr. Reddy’S Laboratories Limited	Stable liquid formulations of cyclophosphamide and processes
US10849916B2 (en)	2014-07-11	2020-12-01	Dr. Reddys Laboratories Limited	Stable liquid formulations of cyclophosphamide and its impurities
AR100034A1 (es)	2015-01-30	2016-09-07	Consejo Nac De Investig Científicas Y Técnicas (Conicet)	Una composición farmacéutica soluble en agua que comprende, al menos, una sustancia terapéuticamente activa y, al menos, una sustancia con capacidad para formar micelas
CN116328361A (zh) *	2023-03-23	2023-06-27	四川汇宇制药股份有限公司	稳定的紫杉醇溶液及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR830002614B1 (ko) *	1980-04-14	1983-05-30	후로인도 산교오 가부시끼 가이샤	활성화된 의약조성물의 제법
JPS61152621A (ja) *	1984-12-27	1986-07-11	Lion Corp	液状透明口腔用組成物
RO92831B1 (ro) *	1985-07-29	1988-01-01	Viorica Dobrescu	Procedeu de purificare a polietilenglicolilor
HU201567B (en) *	1988-07-21	1990-11-28	Gyogyszerkutato Intezet	Process for production of intravenous medical compositions containing cyclosphorin
JPH02196789A (ja) *	1989-01-25	1990-08-03	Sankyo Co Ltd	リゾキシン類化合物の安定化法
FR2678833B1 (fr)	1991-07-08	1995-04-07	Rhone Poulenc Rorer Sa	Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
JP2598206B2 (ja) *	1992-07-17	1997-04-09	ツヤック株式会社	蛋白繊維品のハイグラル・エクスパンションの安定化法
ES2224200T3 (es) *	1992-11-27	2005-03-01	Mayne Pharma (Usa) Inc.	Composicion inyectable estable de paclitaxel.
KR100371062B1 (ko) *	1992-11-27	2003-04-21	에프.에이치.포울딩 앤드 컴퍼니 리미티드	안정성이향상된주사가능한택솔조성물및이를제형화하는방법

1994
- 1994-08-25 TW TW083107808A patent/TW406020B/zh active
- 1994-09-23 NZ NZ264526A patent/NZ264526A/en not_active IP Right Cessation
- 1994-09-26 CZ CZ19942349A patent/CZ287358B6/cs not_active IP Right Cessation
- 1994-09-26 CA CA002132936A patent/CA2132936C/en not_active Expired - Fee Related
- 1994-09-26 ZA ZA947482A patent/ZA947482B/xx unknown
- 1994-09-26 IL IL11106594A patent/IL111065A/xx not_active IP Right Cessation
- 1994-09-26 FI FI944448A patent/FI115825B/fi active IP Right Grant
- 1994-09-27 SG SG1996002365A patent/SG50479A1/en unknown
- 1994-09-27 AT AT94115180T patent/ATE149843T1/de not_active IP Right Cessation
- 1994-09-27 HU HU9402776A patent/HU217962B/hu not_active IP Right Cessation
- 1994-09-27 NO NO943583A patent/NO308447B1/no not_active IP Right Cessation
- 1994-09-27 JP JP23011894A patent/JP3447386B2/ja not_active Expired - Lifetime
- 1994-09-27 EP EP94115180A patent/EP0645145B1/de not_active Expired - Lifetime
- 1994-09-27 DK DK94115180.5T patent/DK0645145T3/da active
- 1994-09-27 DE DE69402022T patent/DE69402022T2/de not_active Expired - Fee Related
- 1994-09-27 ES ES94115180T patent/ES2098842T3/es not_active Expired - Lifetime
- 1994-09-28 IT IT94RM000621A patent/IT1279383B1/it active IP Right Grant
- 1994-09-28 CN CNB941165809A patent/CN1140297C/zh not_active Expired - Fee Related
- 1994-09-28 AU AU74273/94A patent/AU686651B2/en not_active Ceased
- 1994-09-28 BE BE9400879A patent/BE1007987A5/fr not_active IP Right Cessation
- 1994-09-28 RU RU94037231A patent/RU2107500C1/ru not_active IP Right Cessation
- 1994-09-29 PL PL94305240A patent/PL176826B1/pl not_active IP Right Cessation
- 1994-09-29 ES ES09402047A patent/ES2095802A1/es not_active Withdrawn
- 1994-09-29 KR KR1019940025248A patent/KR100515631B1/ko not_active Expired - Fee Related
1995
- 1995-01-18 US US08/374,093 patent/US5504102A/en not_active Expired - Fee Related
1997
- 1997-04-28 BR BR1100361-8A patent/BR1100361A/pt active IP Right Grant
- 1997-05-29 GR GR970401231T patent/GR3023583T3/el unknown
- 1997-06-26 HK HK96797A patent/HK96797A/en not_active IP Right Cessation
1998
- 1998-02-20 CY CY203598A patent/CY2035A/xx unknown
- 1998-06-23 CZ CZ19981998A patent/CZ287485B6/cs not_active IP Right Cessation

Also Published As

Publication number	Publication date
HUT68687A (en)	1995-07-28
ZA947482B (en)	1995-05-15
CY2035A (en)	1998-02-20
HU217962B (hu)	2000-05-28
NO943583D0 (no)	1994-09-27
DE69402022D1 (de)	1997-04-17
BR1100361A (pt)	2000-07-18
US5504102A (en)	1996-04-02
PL176826B1 (pl)	1999-07-30
CZ287485B6 (cs)	2000-12-13
AU7427394A (en)	1995-04-13
CA2132936C (en)	1999-06-29
CN1107367A (zh)	1995-08-30
CN1140297C (zh)	2004-03-03
FI944448A0 (fi)	1994-09-26
JP3447386B2 (ja)	2003-09-16
CZ234994A3 (en)	1995-04-12
ITRM940621A0 (it)	1994-09-28
GR3023583T3 (en)	1997-08-29
NZ264526A (en)	1996-10-28
ATE149843T1 (de)	1997-03-15
SG50479A1 (en)	1998-07-20
KR950007872A (ko)	1995-04-15
IL111065A0 (en)	1994-12-29
EP0645145A3 (de)	1995-05-24
DE69402022T2 (de)	1997-07-17
PL305240A1 (en)	1995-04-03
FI115825B (fi)	2005-07-29
HK96797A (en)	1997-08-08
CA2132936A1 (en)	1995-03-30
IL111065A (en)	2003-03-12
ES2098842T3 (es)	1997-05-01
IT1279383B1 (it)	1997-12-10
HU9402776D0 (en)	1994-12-28
RU2107500C1 (ru)	1998-03-27
NO943583L (no)	1995-03-30
ITRM940621A1 (it)	1996-03-28
TW406020B (en)	2000-09-21
RU94037231A (ru)	1996-09-27
ES2095802A1 (es)	1997-02-16
DK0645145T3 (da)	1997-04-07
EP0645145B1 (de)	1997-03-12
JPH07179362A (ja)	1995-07-18
AU686651B2 (en)	1998-02-12
CZ287358B6 (en)	2000-11-15
BE1007987A5 (fr)	1995-12-05
FI944448L (fi)	1995-03-30
EP0645145A2 (de)	1995-03-29
KR100515631B1 (ko)	2005-12-08

Legal Events

Date	Code	Title	Description
2010-04-26	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO943583D0 (no)	1994-09-27	Stabilisert farmasöytisk preparat og stabiliserende opplösningsmiddel
SE8102193L (sv)	1982-10-07	Terapeutiskt aktiv organisk forening och dess anvendning
IL90052A (en)	1993-07-08	:-substituted 4-(quinolin- 2-yl-methoxy) phenylacetic acids and esters, their preparation and pharmaceutical compositions containing them
HUT53521A (en)	1990-11-28	Process for producing pharmaceutical compositions comprising morphine
IE861813L (en)	1987-01-08	New Polysaccharide Esters and their Salts
AU5612694A (en)	1994-06-22	Injectable composition
ATE84414T1 (de)	1993-01-15	Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eines arneimittels zur behandlung von komplikationen bei diabetes mellitus.
SE8403487L (sv)	1985-01-02	Farmaceutisk komposition
HUT70150A (en)	1995-09-28	Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridines, pharmaceutical compositions containing them and method for its preparation
ATE67406T1 (de)	1991-10-15	Nicorandil enthaltende zubereitung zum einspritzen.
US5037655A (en)	1991-08-06	Method of stabilizing tretinoin
KR900014382A (ko)	1990-10-23	(s)-7-(3-아미노-1-피롤리디닐)-1-시클로프로필-6-플루오로-1,4-디히드로-4-옥소-나프티리딘-3-카르복실산
HU9202850D0 (en)	1992-11-30	Method for preparing quinolyl-methoxy-phenyl-acetamide derivatives substituted by heterocyclic groups and drugs containing the same compounds
KR950702561A (ko)	1995-07-29	퀴놀린 및 나프티리딘 약물 전구체(quinoline and naphthyridine prodrugs)
PT90706A (pt)	1989-12-29	Processo para a preparacao de derivados de antraciclinas dotados de actividade citostatica
ITMI911845A1 (it)	1993-01-04	Uso dei derivati dell'acido benzimidazolin-2-oxo-1-carbossilico.
IL98200A0 (en)	1992-06-21	Pharmaceutical composition containing a derivative of substituted-l-valyl-l-prolinamide
KR900016130A (ko)	1990-11-12	2-피리딜메틸티오 유도체 및 궤양 치료제
IE780530L (en)	1978-09-17	Anti-histamine salts and compositions
ATE2839T1 (de)	1983-04-15	1-(3'-benzofuryl)-4-benzylpiperazin enthaltendes schmerzstillendes arzneimittel und verfahren zu seiner herstellung.
JPS5775996A (en)	1982-05-12	Derivative of 4'''-aminoaclacinomycin a